You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 21, 2024

Litigation Details for LTL Management LLC v. Those Parties Listed on Appendix A to the Complain (Bankr. D.N.J. 2023)

✉ Email this page to a colleague

« Back to Dashboard

LTL Management LLC v. Those Parties Listed on Appendix A to the Complain (Bankr. D.N.J. 2023)

Docket	⤷ Sign Up	Date Filed	2023-04-04
Court	United States Bankruptcy Court, D. New Jersey	Date Terminated
Cause		Assigned To	Michael B. Kaplan
Jury Demand		Referred To
Patents	10,010,507; 10,039,718; 10,052,314; 10,106,548; 10,125,140; 10,143,693; 10,213,386; 7,094,781; 7,514,444; 8,445,507; 8,476,284; 8,497,277; 8,697,711; 8,754,090; 8,754,091; 8,791,122; 8,802,689; 8,952,015; 8,957,079; 9,181,257; 9,284,280; 9,296,753; 9,439,906; 9,481,663; 9,539,218; 9,655,857; 9,725,455; 9,884,054; 9,987,261
Link to Docket	External link to docket

Small Molecule Drugs cited in LTL Management LLC v. Those Parties Listed on Appendix A to the Complain

The small molecule drugs covered by the patents cited in this case are ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , and ⤷ Sign Up .

Details for LTL Management LLC v. Those Parties Listed on Appendix A to the Complain (Bankr. D.N.J. 2023)

+ Get email alerts for changes to this table

Subscribe to access the full database, or Sign Up
Date Filed	Document No.	Description	Snippet	Link To Document
0000-00-00				External link to document
2023-04-19	65	Objection	; 9,181,257; 9,296,753; 9,655,857; 9,725,455; 10,010,507; 10,106,548; and 10,125,140. In June 2019, Pharmacyclics…the Company. Patents The Company’s subsidiaries have made a practice of obtaining patent protection on…of matter patent expires in 2023. The latest expiring European composition of matter patent expires in… has an exclusive license to those patent families. The two patent families both expire in the United…licensed European patent expires in 2032. Janssen Biotech, Inc. owns a separate patent portfolio related	External link to document
>Date Filed	>Document No.	>Description	>Snippet	>Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.